SSelectStock

SENORESSenores Pharmaceuticals Limited

Pharma · Drug Manufacturers - General · NSE · as of 2026-09-11 (delayed ~30 min in market hours)

Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.

1,467.30
0.29%
70Strong

Mkt Cap
₹6,760 Cr
P/E
51.8
P/B
6.3
Div Yield
0.00%
52W High
₹1,599.00
52W Low
₹662.45

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)6,759.70
P/E51.81
P/B6.27
PEG1.23
ROE %12.40
ROCE %10.70
Debt / Equity0.35
EPS28.32
Revenue Growth %38.30
Profit Growth %43.50
Dividend Yield %0.00
Promoter Holding %54.93
FII Holding %10.52
DII Holding %
Beta0.94

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

HOLDConviction 76%

The picture

  • Revenue growth: 38.3% YoY
  • Profit growth: 43.5% YoY
  • Debt/Equity: 0.35
  • RSI: 52
  • Price vs EMA21: above
  • Price vs SMA50: above
  • Pullback to 21-EMA signal (setup quality 63%)

Bull case

  • Revenue growth: 38.3% YoY
  • Profit growth: 43.5% YoY
  • Debt/Equity: 0.35
  • RSI: 52

Bear case

  • ROCE: 10.7%
  • Dividend yield: 0.00%
  • MACD: bearish
  • Volume: 0.6x 20-day average

Key risks

  • ROCE: 10.7%
  • Dividend yield: 0.00%

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹1,467.30
Stop Loss
₹1,396.30
risk 4.8%
Target 1 (1.5R)
₹1,573.81
+7.3%
Target 2 (3R)
₹1,680.31
+14.5%
Support (20d)
₹1,410.40
Resistance (52w)
₹1,599.00
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹71.00/share
ATR (volatility)
₹54.52
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹54.52). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental72
Technical59
Momentum76
Risk (safety)79

Peers — Pharma

CORONA 1.60%
87
GRANULES 1.12%
81
LAURUSLABS 1.23%
79
KPL 3.75%
79
DIVISLAB 1.23%
79
CAPLIPOINT 1.45%
78